Argatroban

被引:51
作者
Kathiresan, S
Shiomura, J
Jang, IK
机构
[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA 02114 USA
[2] Mitsubishi Pharma Corp, Tokyo, Japan
关键词
argatroban; anticoagulation; direct thrombin inhibitor;
D O I
10.1023/A:1015368126304
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Antithrombotic and antiplatelet therapies are the cornerstones of management of cardiovascular disorders today. Due to the safety and efficacy limitations of the classic antithrombotic, unfractionated heparin, considerable effort has been directed at developing novel anticoagulants. Direct thrombin inhibitors as a class of drugs offer inhibition of clot-bound as well as fluid-phase thrombin and a more predictable anticoagulant response. Specifically, argatroban, a synthetic small molecule direct thrombin inhibitor, selectively inhibits the catalytic site of thrombin in a reversible manner. Overall, argatroban's short half-life, ease of monitoring with an activated partial thromboplastin time, and safety in renal failure patients make this drug the preferable mode therapy for prevention of thrombosis in heparin-induced thrombocytopenia. The role of adjunctive argatroban therapy in acute coronary syndromes and during percutaneous coronary intervention is currently being studied.
引用
收藏
页码:41 / 47
页数:7
相关论文
共 35 条
[1]  
Behar S, 1998, CIRCULATION, V98, P453
[2]  
BERRY CN, 1994, THROMB HAEMOSTASIS, V72, P381
[3]   Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. [J].
Cannon, CP ;
Weintraub, WS ;
Demopoulos, LA ;
Vicari, R ;
Frey, MJ ;
Lakkis, N ;
Neumann, FJ ;
Robertson, DH ;
DeLucca, PT ;
DiBattiste, PM ;
Gibson, CM ;
Braunwald, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (25) :1879-1887
[4]  
Cody RJ, 1997, J AM COLL CARDIOL, V30, P1
[5]   Thrombin signalling and protease-activated receptors [J].
Coughlin, SR .
NATURE, 2000, 407 (6801) :258-264
[6]   EVIDENCE FOR A REBOUND COAGULATION PHENOMENON AFTER CESSATION OF A 4-HOUR INFUSION OF A SPECIFIC THROMBIN INHIBITOR IN PATIENTS WITH UNSTABLE ANGINA-PECTORIS [J].
GOLD, HK ;
TORRES, FW ;
GARABEDIAN, HD ;
WERNER, W ;
JANG, IK ;
KHAN, A ;
HAGSTROM, JN ;
YASUDA, T ;
LEINBACH, RC ;
NEWELL, JB ;
BOVILL, EG ;
STUMP, DC ;
COLLEN, D .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1993, 21 (05) :1039-1047
[7]   No effect of clot age or thrombolysis on argatroban's inhibition of thrombin [J].
Hantgan, RR ;
Jerome, WG ;
Hursting, MJ .
BLOOD, 1998, 92 (06) :2064-2074
[8]  
HERRMAN PR, 1996, J THROMB THROMBOLYS, V3, P367
[9]   New anticoagulants [J].
Hirsh, J .
AMERICAN HEART JOURNAL, 2001, 142 (02) :S3-S8
[10]   HEPARIN - MECHANISM OF ACTION, PHARMACOKINETICS, DOSING CONSIDERATIONS, MONITORING, EFFICACY, AND SAFETY [J].
HIRSH, J ;
RASCHKE, R ;
WARKENTIN, TE ;
DALEN, JE ;
DEYKIN, D ;
POLLER, L .
CHEST, 1995, 108 (04) :S258-S275